Charles Schwab Investment Management Inc. Has $713,000 Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Charles Schwab Investment Management Inc. increased its position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 14.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 173,063 shares of the company’s stock after purchasing an additional 22,145 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.23% of Trevi Therapeutics worth $713,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the company. Geode Capital Management LLC lifted its position in shares of Trevi Therapeutics by 10.2% in the third quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock valued at $4,223,000 after buying an additional 117,418 shares during the last quarter. State Street Corp raised its stake in Trevi Therapeutics by 5.9% in the 3rd quarter. State Street Corp now owns 952,912 shares of the company’s stock valued at $3,183,000 after acquiring an additional 53,051 shares during the period. Bank of New York Mellon Corp lifted its holdings in Trevi Therapeutics by 2.1% during the 4th quarter. Bank of New York Mellon Corp now owns 140,219 shares of the company’s stock valued at $578,000 after purchasing an additional 2,935 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Trevi Therapeutics by 220.6% during the third quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company’s stock worth $336,000 after purchasing an additional 69,167 shares during the period. Finally, Barclays PLC increased its holdings in shares of Trevi Therapeutics by 180.8% in the third quarter. Barclays PLC now owns 95,232 shares of the company’s stock valued at $319,000 after purchasing an additional 61,317 shares during the last quarter. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Trevi Therapeutics Trading Down 3.2 %

Shares of TRVI stock opened at $6.29 on Tuesday. The stock has a 50 day simple moving average of $4.92 and a 200 day simple moving average of $3.90. Trevi Therapeutics, Inc. has a 1 year low of $2.30 and a 1 year high of $7.39. The stock has a market cap of $608.13 million, a P/E ratio of -14.30 and a beta of 0.90.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. Analysts forecast that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.

Analysts Set New Price Targets

TRVI has been the subject of several research analyst reports. Raymond James raised shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $9.00 to $29.00 in a report on Monday, March 10th. B. Riley restated a “buy” rating and set a $20.00 price objective (up previously from $11.00) on shares of Trevi Therapeutics in a report on Wednesday, March 19th. HC Wainwright reaffirmed a “buy” rating and issued a $12.50 target price on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. D. Boral Capital reissued a “buy” rating and set a $21.00 price target on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Finally, Oppenheimer upped their price objective on Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, March 11th. Seven equities research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, Trevi Therapeutics has an average rating of “Buy” and a consensus price target of $17.56.

Insider Transactions at Trevi Therapeutics

In other Trevi Therapeutics news, insider Farrell Simon sold 81,313 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the transaction, the insider now directly owns 76,900 shares in the company, valued at $519,075. The trade was a 51.39 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Jennifer L. Good sold 5,263 shares of the firm’s stock in a transaction on Friday, March 21st. The shares were sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the sale, the chief executive officer now directly owns 213,313 shares in the company, valued at approximately $1,403,599.54. This represents a 2.41 % decrease in their position. The disclosure for this sale can be found here. 24.37% of the stock is currently owned by insiders.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.